114 related articles for article (PubMed ID: 24469650)
1. The comparison between human leukocyte antigen system incidence in patients with bladder cancer and normal controls.
Falahatkar S; Donyamali H; Joafshani MA; Shahrokhi Damavand R; Hoda S; Esmaeili S; Gholamjani Moghaddam K; Nikpour S
Urol J; 2014 Jan; 10(4):1059-62. PubMed ID: 24469650
[TBL] [Abstract][Full Text] [Related]
2. Types of HLA in the bladder transitional cell carcinoma (TCC).
Yılmaz E; Uğur Özalp A; Cekmen A; Eren B; Onal B; Akkuş E; Erdoğan E
Med Glas (Zenica); 2013 Feb; 10(1):133-6. PubMed ID: 23348175
[TBL] [Abstract][Full Text] [Related]
3. Association between HLA antigens and bladder tumors.
Tokuç R; Akdaş A; Ozerkan K; Remzi D
Eur Urol; 1987; 13(3):207-9. PubMed ID: 3497040
[TBL] [Abstract][Full Text] [Related]
4. Expression of miR-100 as a novel ancillary non-invasive biomarker for early detection of bladder carcinoma.
Qureshi A; Fahim A; Kazi N; Farsi Kazi SA; Nadeem F
J Pak Med Assoc; 2018 May; 68(5):759-763. PubMed ID: 29885177
[TBL] [Abstract][Full Text] [Related]
5. Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer.
Andrews B; Shariat SF; Kim JH; Wheeler TM; Slawin KM; Lerner SP
J Urol; 2002 Mar; 167(3):1475-81. PubMed ID: 11832773
[TBL] [Abstract][Full Text] [Related]
6. Antigenic detection and prognosis of patients with transitional cell carcinoma of the urinary bladder.
Tan LB; Lin LM; Huang CH; Chiang CP; Chien CH; Pan CC
Urol Int; 1989; 44(5):264-71. PubMed ID: 2800062
[TBL] [Abstract][Full Text] [Related]
7. Tumor-specific upregulation of human leukocyte antigen-G expression in bladder transitional cell carcinoma.
Gan LH; Huang LF; Zhang X; Lin A; Xu DP; Wang Q; Wang TJ; Yan WH
Hum Immunol; 2010 Sep; 71(9):899-904. PubMed ID: 20600448
[TBL] [Abstract][Full Text] [Related]
8. B5 tumour marker and urine cytology in diagnosis and follow-up of transitional cell bladder cancer.
Malpani K; Metcalfe SM; Hinchliffe A
Br J Urol; 1989 Sep; 64(3):257-62. PubMed ID: 2804562
[TBL] [Abstract][Full Text] [Related]
9. CLINICO-PATHOLOGICAL PATTERN, CLASSIFICATION AND STAGING OF URINARY BLADDER CARCINOMAS--A FIVE YEARS EXPERIENCE AT A TERTIARY CARE HOSPITAL IN CENTRAL PUNJAB.
Naeem A; Naseem N; Anwar S; Butt S; Nagi AH
J Ayub Med Coll Abbottabad; 2015; 27(1):131-4. PubMed ID: 26182758
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.
Mizutani Y; Matsubara H; Yamamoto K; Nan Li Y; Mikami K; Okihara K; Kawauchi A; Bonavida B; Miki T
Cancer; 2004 Oct; 101(8):1794-802. PubMed ID: 15386310
[TBL] [Abstract][Full Text] [Related]
11. Clinical use of serum CA-125 levels in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
Kouba EJ; Lentz A; Wallen EM; Pruthi RS
Urol Oncol; 2009; 27(5):486-90. PubMed ID: 18555706
[TBL] [Abstract][Full Text] [Related]
12. Blood group isoantigens ABO (H) in transitional carcinoma of the bladder: a clinicopathological study.
Cuadrado E; Rodriguez-Trinidad A; Blasco E; Torrado J; Lopez Garcia JA; Arozena F
J Urol; 1986 Feb; 135(2):409-15. PubMed ID: 3511295
[TBL] [Abstract][Full Text] [Related]
13. The impact of the AB0 and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy.
Engel O; Soave A; Peine S; Kluth LA; Schmid M; Shariat SF; Dahlem R; Fisch M; Rink M
World J Urol; 2015 Nov; 33(11):1769-76. PubMed ID: 25782867
[TBL] [Abstract][Full Text] [Related]
14. Correlation of the cell surface antigens with stage and grade in cancer of the bladder.
Emmott RC; Javadpour N; Bergman SM; Soares T
J Urol; 1979 Jan; 121(1):37-9. PubMed ID: 759641
[TBL] [Abstract][Full Text] [Related]
15. ABO blood groups and bladder carcinoma.
Llopis B; Ruiz JL; Server G; Marty M; Gallego J; Jiménez-Cruz JF
Eur Urol; 1990; 17(4):289-92. PubMed ID: 2364966
[TBL] [Abstract][Full Text] [Related]
16. Independent prognostic value of serum hepatocyte growth factor in bladder cancer.
Gohji K; Nomi M; Niitani Y; Kitazawa S; Fujii A; Katsuoka Y; Nakajima M
J Clin Oncol; 2000 Aug; 18(16):2963-71. PubMed ID: 10944129
[TBL] [Abstract][Full Text] [Related]
17. Relationship between blood groups and tumour grade, number, size, stage, recurrence and survival in patients with transitional cell carcinoma of the bladder.
Raitanen MP; Tammela TL
Scand J Urol Nephrol; 1993; 27(3):343-7. PubMed ID: 8290914
[TBL] [Abstract][Full Text] [Related]
18. Significance of serum laminin P1 values in patients with transitional cell carcinoma of the bladder.
Mungan U; Kirkali G; Celebi I; Kirkali Z
Urology; 1996 Sep; 48(3):496-500. PubMed ID: 8804512
[TBL] [Abstract][Full Text] [Related]
19. Analysis of tissue ABH antigens in superficial bladder tumours.
Tsujihashi H; Matsuda H; Uejima S; Akiyama T; Kurita T
Int Urol Nephrol; 1991; 23(1):37-44. PubMed ID: 1938218
[TBL] [Abstract][Full Text] [Related]
20. Blood group H antigen in transitional carcinoma of the urinary bladder.
Tichý M; Tichá V; Jansa P; Student V; Vanák J
Acta Univ Palacki Olomuc Fac Med; 1991; 130():157-62. PubMed ID: 1838863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
